Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Condition: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine; Biological: Meningococcal Group B Vaccine (Trumenba®); Biological: Meningococcal group B Vaccine (Bexsero®) Sponsor: Sanofi Pasteur, a Sanofi Company Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | Men | Meningitis | Meningitis Vaccine | Research | Study | Tetanus | Tetanus Vaccine | Vaccines